Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30969271 | 0.87 | NPC1 (0.73) | LMNAALDH1A1HPGDMEN1HTT | |
| SCHEMBL3216808 | 0.85 | ATM (0.74) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3203432 | 0.84 | ALDH1A1 (0.74) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9921691 | 0.84 | ATM (0.76) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30969294 | 0.83 | POLB (0.70) | ATMLMNASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL16900138 | 0.83 | POLB (0.63) | ATMLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6555426 | 0.82 | ALDH1A1 (0.80) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL403057 | 0.82 | ATM (0.74) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13025526 | 0.82 | ATM (0.74) | ATMLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10122851 | 0.82 | LMNA (1.00) | ATMLMNASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| EP-4642766-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145585-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | ATM 844/4885LMNA 1934/4885SMN1; SMN2 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.